SAGE - Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data

2024-05-30 12:24:45 ET

Summary

• Sage Therapeutics, Inc. results from phase 2b KINETIC 2 Study, using SAGE-324 for the treatment of patients with essential tremor, expected mid-2024.
• Top-line data from the phase 3 SURVEYOR study, using SAGE-718 for cognitive impairment in HD patients, expected in mid-2024.
• Top-line data from the phase 2 DIMENSION study, using SAGE-718 for cognitive impairment in HD patients, expected late-2024.
• Top-line data from the phase 2 LIGHTWAVE Study, using SAGE-718 for mild cognitive impairment or mild dementia due to Alzheimer's Disease, expected late-2024.

Sage Therapeutics, Inc. ( SAGE ) stock remains a hold for now. The reason why I think this stock should be a "hold" rating is because it expects to report results from its phase 2b KINETIC 2 Study, which is using SAGE-324 for the treatment of patients with Essential Tremor [ET]. Such results are expected to be released in mid-2024, and this will be a huge inflection point for this biotech. I believe that this is the last shot for it to perform well....

For further details see: